Could zapping kidney nerves tame stubborn high blood pressure and save hearts?
NCT ID NCT07602790
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a procedure called renal denervation, which uses a catheter to calm overactive nerves in the kidneys, in 1,000 people with both resistant hypertension and multivessel coronary artery disease. Participants will undergo the procedure during a planned heart stent operation and be followed for heart attacks, strokes, hospitalizations, and blood pressure changes. The goal is to see if this nerve treatment can reduce serious heart events better than standard blood pressure medications alone.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- renal denervation procedure
- What this could lead to
- If it works, this could offer a new way to control blood pressure and reduce heart attacks, strokes, and hospitalizations in people with both resistant hypertension and severe coronary artery disease.
- What could go wrong
- This is an early-stage study with no phase assigned, so results are uncertain. The procedure carries risks like kidney artery damage or contrast-related kidney injury, and it may not lower blood pressure enough to prevent heart events.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 1,000 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Nov 2026
An estimate. Start dates often move.
- Expected to finish
-
Nov 2033
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Subject with multi-vessel disease * Having successful index PCI and planned staged procedure within 1-6 weeks to complete revascularization * Subjects ≥21 years of age * Office systolic blood pressure at index procedure and/or staged procedure (systolic blood pressure \>140 mmHg) while taking 2 or more antihypertensive drugs * Subject agrees to have all study procedures performed, and is competent and willing to provide written, informed consent to participate in this clinical study prior to staged procedure Exclusion Criteria: * \- Contraindication for RDN outlined by IFU * Acute MI at time of the staged PCI procedure (AMI at time of the index PCI is allowed) * Subject has undergone prior renal denervation. * Subject has renal artery anatomy that is ineligible for RDN treatment per Symplicity Spyral™ IFU * Known secondary cause (e.g., renal artery stenosis, primary aldosteronism, pheochromocytoma, Cushing's syndrome, or other identifiable etiologies). * Severe renal failure (eGFR \<30 ml/min/1.73 m²) * Known LVEF \<30% * Known history of polycystic kidney disease, unilateral kidney, or undergone renal transplant * Mechanical circulatory support during PCI * Subject is under judicial protection, tutorship or curatorship * Failure of index procedure * Acute MI, severe renal failure, need for mechanical circulatory support, or legal incapacity between the index and staged procedures resulting in loss of eligibility.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hypertension, resistant to conventional therapy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Timing of additional artery opening after heart attack could save lives
- Could a pacemaker also treat high blood pressure? a new device aims to do both.
- Could a pacemaker tame stubborn high blood pressure?
- Can a simple blood test and CT scan predict bypass success?
- Double vision for heart stents: could two scans beat one?
- Wire-Free heart scan could cut unnecessary stents in heart attack patients